Cargando…

AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals

BACKGROUND: Reactive oxygen species (ROS) has very important role in male infertility area. Until now medication for treatment of male infertility is not produced. MOTILIPERM was prepared as a mixture of extracts of three medicinal herbs [roots of Morinda officinalis How (Rubiaceae), outer scales of...

Descripción completa

Detalles Bibliográficos
Autor principal: Park, Jong Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186727/
http://dx.doi.org/10.21037/tau.2018.AB032
_version_ 1783362890122657792
author Park, Jong Kwan
author_facet Park, Jong Kwan
author_sort Park, Jong Kwan
collection PubMed
description BACKGROUND: Reactive oxygen species (ROS) has very important role in male infertility area. Until now medication for treatment of male infertility is not produced. MOTILIPERM was prepared as a mixture of extracts of three medicinal herbs [roots of Morinda officinalis How (Rubiaceae), outer scales of Allium cepa L. (Liliaceae) and seeds of Cuscuta chinensis Lamark (Convolvulaceae)]. To investigate the role of ROS-based endoplasmic reticulum (ER) stress in a rat model of varicocele (VC), an animal model that was treated with cisplatin (CIS), adriamycin or 5 alpha reductase inhibitor (finasteride, FINA) and the therapeutic efficacy of MOTILIPERM in those infertile male rats, we have researched. METHODS: We evaluated the rat those were administered C or F and the rat were induced VC. We also evaluated the effect and adverse events of the MOTILIPERM in the rats. Male rats were divided into several groups such as a normal control group (CTR + vehicle), a control group administered MOTILIPERM 200 mg/kg (CTR + M 200), a VC-induced or FINA, CIS or adriamycin administered group (VC + vehicle or FINA + vehicle, CIS + vehicle or adriamycin + vehicle) and VC-induced groups that was administered MOTILIPERM 100 (VC + M 100) or 200 (VC + M 200) mg/kg and administered with CIS, FINA or adriamycin plus MOTILIPERM 100 (CIS or FINA + M 100) or 200 (CIS or FINA + M 200) mg/kg. Testis weights were recorded and serums were assayed for hormone concentrations. Tissues were subjected to semen analysis, histopathology, analyses of ER response protein expression levels and oxidative stress was assessed by measuring ROS, reactive nitrogen species (RNS), malondialdehyde (MDA) level and ratios of total glutathione (GSH)/oxidized GSH (GSSG). RESULTS: MOTILIPERM treatment of VC-induced groups or the groups administered FINA, CIS, adriamycin significantly increased left testis weight, testosterone level, sperm motility, count and spermatogenic cell density. MOTILIPERM treatment also decreased MDA and ROS/RNS level but increased GSH/GSSG ratio. CONCLUSIONS: This study suggests that ROS-related ER stress may plays a major role in VC-induced or FINA, CIS or adriamycin induced male infertility. MOTILIPERM, a novel compound targeting ROS-based ER stress, may be therapeutically useful in the VC induced infertility treatment and FINA, CIS or adriamycin induced male infertility as a supplement or herbal medication.
format Online
Article
Text
id pubmed-6186727
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-61867272018-10-26 AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals Park, Jong Kwan Transl Androl Urol Podium Lecture BACKGROUND: Reactive oxygen species (ROS) has very important role in male infertility area. Until now medication for treatment of male infertility is not produced. MOTILIPERM was prepared as a mixture of extracts of three medicinal herbs [roots of Morinda officinalis How (Rubiaceae), outer scales of Allium cepa L. (Liliaceae) and seeds of Cuscuta chinensis Lamark (Convolvulaceae)]. To investigate the role of ROS-based endoplasmic reticulum (ER) stress in a rat model of varicocele (VC), an animal model that was treated with cisplatin (CIS), adriamycin or 5 alpha reductase inhibitor (finasteride, FINA) and the therapeutic efficacy of MOTILIPERM in those infertile male rats, we have researched. METHODS: We evaluated the rat those were administered C or F and the rat were induced VC. We also evaluated the effect and adverse events of the MOTILIPERM in the rats. Male rats were divided into several groups such as a normal control group (CTR + vehicle), a control group administered MOTILIPERM 200 mg/kg (CTR + M 200), a VC-induced or FINA, CIS or adriamycin administered group (VC + vehicle or FINA + vehicle, CIS + vehicle or adriamycin + vehicle) and VC-induced groups that was administered MOTILIPERM 100 (VC + M 100) or 200 (VC + M 200) mg/kg and administered with CIS, FINA or adriamycin plus MOTILIPERM 100 (CIS or FINA + M 100) or 200 (CIS or FINA + M 200) mg/kg. Testis weights were recorded and serums were assayed for hormone concentrations. Tissues were subjected to semen analysis, histopathology, analyses of ER response protein expression levels and oxidative stress was assessed by measuring ROS, reactive nitrogen species (RNS), malondialdehyde (MDA) level and ratios of total glutathione (GSH)/oxidized GSH (GSSG). RESULTS: MOTILIPERM treatment of VC-induced groups or the groups administered FINA, CIS, adriamycin significantly increased left testis weight, testosterone level, sperm motility, count and spermatogenic cell density. MOTILIPERM treatment also decreased MDA and ROS/RNS level but increased GSH/GSSG ratio. CONCLUSIONS: This study suggests that ROS-related ER stress may plays a major role in VC-induced or FINA, CIS or adriamycin induced male infertility. MOTILIPERM, a novel compound targeting ROS-based ER stress, may be therapeutically useful in the VC induced infertility treatment and FINA, CIS or adriamycin induced male infertility as a supplement or herbal medication. AME Publishing Company 2018-09 /pmc/articles/PMC6186727/ http://dx.doi.org/10.21037/tau.2018.AB032 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Podium Lecture
Park, Jong Kwan
AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
title AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
title_full AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
title_fullStr AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
title_full_unstemmed AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
title_short AB032. Development of new treatment modality for male infertility by using phytopharmaceuticals
title_sort ab032. development of new treatment modality for male infertility by using phytopharmaceuticals
topic Podium Lecture
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186727/
http://dx.doi.org/10.21037/tau.2018.AB032
work_keys_str_mv AT parkjongkwan ab032developmentofnewtreatmentmodalityformaleinfertilitybyusingphytopharmaceuticals